Tratamiento biológico de la artritis reumatoide en España. Análisis de impacto presupuestario de la utilización de certolizumab pegol View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-09

AUTHORS

Álvaro Hidalgo, Renata Villoro, Alexandra Ivanova, Alberto Morell, Pablo Talavera, Belén Ferro

ABSTRACT

Estimar el impacto presupuestario (IP) en España del uso combinado de certolizumab pegol (siguiendo un régimen fijo de dosis subcutáneas cada 2 semanas, tras una dosis de inducción en las semanas 0, 2 y 4) más metotrexato (MTX), como terapia para la artritis reumatoide (AR) de moderada a grave. Se diseñó un modelo desde la perspectiva del Sistema Nacional de Salud (SNS) con un horizonte temporal de 5 años (2013–2017). Se estimó la población candidata a esta terapia frente a otras terapias biológicas para la AR ([abatacept, adalimumab, etanercept, infliximab, tocilizumab, golimumab y rituximab] + [MTX]) a partir de información epidemiológica y la revisión de publicaciones científicas. Se incluyeron los costes: farmacológicos, de administración y de monitorización (año base 2013). Se realizó un análisis de sensibilidad univariante sobre el conjunto de variables con mayor incertidumbre y se aplicó una tasa de descuento anual del 3%. Con las asunciones hechas en el modelo, la cifra de pacientes tratados con certolizumab pegol evolucionaría de 1.943 pacientes en 2013 a 6.234 en 2017. El modelo estima que durante el período 2013–2017 la utilización de certolizumab pegol en España generaría unos ahorros globales medios por valor de 10,26 millones de euros. Dichos ahorros serían debidos fundamentalmente a la reducción de los costes de administración y la ausencia de necesidad de intensificación de dosis o ajustes por peso del paciente. El tratamiento de los pacientes con AR de moderada a grave en España con certolizumab pegol permitiría ahorros en el SNS español en el período 2013–2017. More... »

PAGES

97-107

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40277-013-0019-2

DOI

http://dx.doi.org/10.1007/s40277-013-0019-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1038659265


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Castile-La Mancha", 
          "id": "https://www.grid.ac/institutes/grid.8048.4", 
          "name": [
            "Facultad de Ciencias Jur\u00eddicas y Sociales, Universidad de Castilla la Mancha, Cobertizo San Pedro M\u00e1rtir, S/N, 45071, Toledo, Espa\u00f1a"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hidalgo", 
        "givenName": "\u00c1lvaro", 
        "id": "sg:person.0664515167.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0664515167.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Instituto Max Weber, Madrid, Espa\u00f1a"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Villoro", 
        "givenName": "Renata", 
        "id": "sg:person.01172643353.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172643353.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Instituto Max Weber, Madrid, Espa\u00f1a"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ivanova", 
        "givenName": "Alexandra", 
        "id": "sg:person.016141511515.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016141511515.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital Universitario de La Princesa", 
          "id": "https://www.grid.ac/institutes/grid.411251.2", 
          "name": [
            "Servicio Farmacia, Hospital La Princesa, Madrid, Espa\u00f1a"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morell", 
        "givenName": "Alberto", 
        "id": "sg:person.013617467435.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013617467435.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "UCB Pharma (Spain)", 
          "id": "https://www.grid.ac/institutes/grid.497645.d", 
          "name": [
            "Departamento M\u00e9dico, UCB Pharma, Madrid, Espa\u00f1a"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Talavera", 
        "givenName": "Pablo", 
        "id": "sg:person.01303605541.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303605541.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "UCB Pharma (Spain)", 
          "id": "https://www.grid.ac/institutes/grid.497645.d", 
          "name": [
            "Departamento de Farmacoeconom\u00eda, UCB Pharma, Madrid, Espa\u00f1a"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ferro", 
        "givenName": "Bel\u00e9n", 
        "id": "sg:person.01351720741.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351720741.49"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1136/ard.2008.101659", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003597473"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.reuma.2009.10.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019555626"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf03320900", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021667105", 
          "https://doi.org/10.1007/bf03320900"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.23964", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027969659"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/rheumatology/kem115", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033991351"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.10308", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036303043"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.reuma.2010.03.007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038036734"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.22527", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038726357"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1524-4733.2007.00187.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045102741"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/ard.2008.099291", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046023242"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/rheumatology/kes082", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053312193"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3310/hta10420", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071138943"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-09", 
    "datePublishedReg": "2014-09-01", 
    "description": "Estimar el impacto presupuestario (IP) en Espa\u00f1a del uso combinado de certolizumab pegol (siguiendo un r\u00e9gimen fijo de dosis subcut\u00e1neas cada 2 semanas, tras una dosis de inducci\u00f3n en las semanas 0, 2 y 4) m\u00e1s metotrexato (MTX), como terapia para la artritis reumatoide (AR) de moderada a grave. Se dise\u00f1\u00f3 un modelo desde la perspectiva del Sistema Nacional de Salud (SNS) con un horizonte temporal de 5 a\u00f1os (2013\u20132017). Se estim\u00f3 la poblaci\u00f3n candidata a esta terapia frente a otras terapias biol\u00f3gicas para la AR ([abatacept, adalimumab, etanercept, infliximab, tocilizumab, golimumab y rituximab] + [MTX]) a partir de informaci\u00f3n epidemiol\u00f3gica y la revisi\u00f3n de publicaciones cient\u00edficas. Se incluyeron los costes: farmacol\u00f3gicos, de administraci\u00f3n y de monitorizaci\u00f3n (a\u00f1o base 2013). Se realiz\u00f3 un an\u00e1lisis de sensibilidad univariante sobre el conjunto de variables con mayor incertidumbre y se aplic\u00f3 una tasa de descuento anual del 3%. Con las asunciones hechas en el modelo, la cifra de pacientes tratados con certolizumab pegol evolucionar\u00eda de 1.943 pacientes en 2013 a 6.234 en 2017. El modelo estima que durante el per\u00edodo 2013\u20132017 la utilizaci\u00f3n de certolizumab pegol en Espa\u00f1a generar\u00eda unos ahorros globales medios por valor de 10,26 millones de euros. Dichos ahorros ser\u00edan debidos fundamentalmente a la reducci\u00f3n de los costes de administraci\u00f3n y la ausencia de necesidad de intensificaci\u00f3n de dosis o ajustes por peso del paciente. El tratamiento de los pacientes con AR de moderada a grave en Espa\u00f1a con certolizumab pegol permitir\u00eda ahorros en el SNS espa\u00f1ol en el per\u00edodo 2013\u20132017.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s40277-013-0019-2", 
    "inLanguage": [
      "es"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044191", 
        "issn": [
          "1695-405X", 
          "1989-5453"
        ], 
        "name": "PharmacoEconomics Spanish Research Articles", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "11"
      }
    ], 
    "name": "Tratamiento biol\u00f3gico de la artritis reumatoide en Espa\u00f1a. An\u00e1lisis de impacto presupuestario de la utilizaci\u00f3n de certolizumab pegol", 
    "pagination": "97-107", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "b827ca1e34a169ab15ad3d35e7f509ed006fe7b6d8f184913fb8f8f00ff3201b"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40277-013-0019-2"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1038659265"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40277-013-0019-2", 
      "https://app.dimensions.ai/details/publication/pub.1038659265"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:50", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000347_0000000347/records_89786_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs40277-013-0019-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40277-013-0019-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40277-013-0019-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40277-013-0019-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40277-013-0019-2'


 

This table displays all metadata directly associated to this object as RDF triples.

136 TRIPLES      20 PREDICATES      37 URIs      19 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40277-013-0019-2 schema:author Nef88d476b83442c7af76063191f7cd60
2 schema:citation sg:pub.10.1007/bf03320900
3 https://doi.org/10.1002/art.10308
4 https://doi.org/10.1002/art.22527
5 https://doi.org/10.1002/art.23964
6 https://doi.org/10.1016/j.reuma.2009.10.006
7 https://doi.org/10.1016/j.reuma.2010.03.007
8 https://doi.org/10.1093/rheumatology/kem115
9 https://doi.org/10.1093/rheumatology/kes082
10 https://doi.org/10.1111/j.1524-4733.2007.00187.x
11 https://doi.org/10.1136/ard.2008.099291
12 https://doi.org/10.1136/ard.2008.101659
13 https://doi.org/10.3310/hta10420
14 schema:datePublished 2014-09
15 schema:datePublishedReg 2014-09-01
16 schema:description Estimar el impacto presupuestario (IP) en España del uso combinado de certolizumab pegol (siguiendo un régimen fijo de dosis subcutáneas cada 2 semanas, tras una dosis de inducción en las semanas 0, 2 y 4) más metotrexato (MTX), como terapia para la artritis reumatoide (AR) de moderada a grave. Se diseñó un modelo desde la perspectiva del Sistema Nacional de Salud (SNS) con un horizonte temporal de 5 años (2013–2017). Se estimó la población candidata a esta terapia frente a otras terapias biológicas para la AR ([abatacept, adalimumab, etanercept, infliximab, tocilizumab, golimumab y rituximab] + [MTX]) a partir de información epidemiológica y la revisión de publicaciones científicas. Se incluyeron los costes: farmacológicos, de administración y de monitorización (año base 2013). Se realizó un análisis de sensibilidad univariante sobre el conjunto de variables con mayor incertidumbre y se aplicó una tasa de descuento anual del 3%. Con las asunciones hechas en el modelo, la cifra de pacientes tratados con certolizumab pegol evolucionaría de 1.943 pacientes en 2013 a 6.234 en 2017. El modelo estima que durante el período 2013–2017 la utilización de certolizumab pegol en España generaría unos ahorros globales medios por valor de 10,26 millones de euros. Dichos ahorros serían debidos fundamentalmente a la reducción de los costes de administración y la ausencia de necesidad de intensificación de dosis o ajustes por peso del paciente. El tratamiento de los pacientes con AR de moderada a grave en España con certolizumab pegol permitiría ahorros en el SNS español en el período 2013–2017.
17 schema:genre research_article
18 schema:inLanguage es
19 schema:isAccessibleForFree true
20 schema:isPartOf N43e99d0c82314fadb3a216599b1bfdff
21 Ne38cc0b1f58c4f1bb83107fd4f8e9313
22 sg:journal.1044191
23 schema:name Tratamiento biológico de la artritis reumatoide en España. Análisis de impacto presupuestario de la utilización de certolizumab pegol
24 schema:pagination 97-107
25 schema:productId N8106bbcad6c040faa52208aa4a7a6af5
26 N8213343746664c2396b43a07d422f9f9
27 Ncfee0dd983ac4870afd09d4be3ebeae7
28 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038659265
29 https://doi.org/10.1007/s40277-013-0019-2
30 schema:sdDatePublished 2019-04-11T09:50
31 schema:sdLicense https://scigraph.springernature.com/explorer/license/
32 schema:sdPublisher Nbe2b7ad18ecb4ea9a7ae6fea2b62c89d
33 schema:url http://link.springer.com/10.1007%2Fs40277-013-0019-2
34 sgo:license sg:explorer/license/
35 sgo:sdDataset articles
36 rdf:type schema:ScholarlyArticle
37 N076f56325bc34c5c9d7c7ed03b96e8b0 schema:name Instituto Max Weber, Madrid, España
38 rdf:type schema:Organization
39 N09d3cfbe432e49a288c1e07c4eac1616 rdf:first sg:person.016141511515.09
40 rdf:rest N4cd6d87965b94fd5a9acb4f0d8045f08
41 N3a0486b3b00940ef874e853dc352dbca rdf:first sg:person.01351720741.49
42 rdf:rest rdf:nil
43 N43e99d0c82314fadb3a216599b1bfdff schema:volumeNumber 11
44 rdf:type schema:PublicationVolume
45 N4cd6d87965b94fd5a9acb4f0d8045f08 rdf:first sg:person.013617467435.20
46 rdf:rest Ne40acf028c0448a9b991a49b0ed97b3a
47 N6f3cd86f900542d6afbca62e15d9e2f5 schema:name Instituto Max Weber, Madrid, España
48 rdf:type schema:Organization
49 N8106bbcad6c040faa52208aa4a7a6af5 schema:name doi
50 schema:value 10.1007/s40277-013-0019-2
51 rdf:type schema:PropertyValue
52 N8213343746664c2396b43a07d422f9f9 schema:name readcube_id
53 schema:value b827ca1e34a169ab15ad3d35e7f509ed006fe7b6d8f184913fb8f8f00ff3201b
54 rdf:type schema:PropertyValue
55 Nb160694fd71142d5a77d771719db8c59 rdf:first sg:person.01172643353.34
56 rdf:rest N09d3cfbe432e49a288c1e07c4eac1616
57 Nbe2b7ad18ecb4ea9a7ae6fea2b62c89d schema:name Springer Nature - SN SciGraph project
58 rdf:type schema:Organization
59 Ncfee0dd983ac4870afd09d4be3ebeae7 schema:name dimensions_id
60 schema:value pub.1038659265
61 rdf:type schema:PropertyValue
62 Ne38cc0b1f58c4f1bb83107fd4f8e9313 schema:issueNumber 3
63 rdf:type schema:PublicationIssue
64 Ne40acf028c0448a9b991a49b0ed97b3a rdf:first sg:person.01303605541.60
65 rdf:rest N3a0486b3b00940ef874e853dc352dbca
66 Nef88d476b83442c7af76063191f7cd60 rdf:first sg:person.0664515167.66
67 rdf:rest Nb160694fd71142d5a77d771719db8c59
68 sg:journal.1044191 schema:issn 1695-405X
69 1989-5453
70 schema:name PharmacoEconomics Spanish Research Articles
71 rdf:type schema:Periodical
72 sg:person.01172643353.34 schema:affiliation N6f3cd86f900542d6afbca62e15d9e2f5
73 schema:familyName Villoro
74 schema:givenName Renata
75 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172643353.34
76 rdf:type schema:Person
77 sg:person.01303605541.60 schema:affiliation https://www.grid.ac/institutes/grid.497645.d
78 schema:familyName Talavera
79 schema:givenName Pablo
80 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303605541.60
81 rdf:type schema:Person
82 sg:person.01351720741.49 schema:affiliation https://www.grid.ac/institutes/grid.497645.d
83 schema:familyName Ferro
84 schema:givenName Belén
85 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351720741.49
86 rdf:type schema:Person
87 sg:person.013617467435.20 schema:affiliation https://www.grid.ac/institutes/grid.411251.2
88 schema:familyName Morell
89 schema:givenName Alberto
90 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013617467435.20
91 rdf:type schema:Person
92 sg:person.016141511515.09 schema:affiliation N076f56325bc34c5c9d7c7ed03b96e8b0
93 schema:familyName Ivanova
94 schema:givenName Alexandra
95 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016141511515.09
96 rdf:type schema:Person
97 sg:person.0664515167.66 schema:affiliation https://www.grid.ac/institutes/grid.8048.4
98 schema:familyName Hidalgo
99 schema:givenName Álvaro
100 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0664515167.66
101 rdf:type schema:Person
102 sg:pub.10.1007/bf03320900 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021667105
103 https://doi.org/10.1007/bf03320900
104 rdf:type schema:CreativeWork
105 https://doi.org/10.1002/art.10308 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036303043
106 rdf:type schema:CreativeWork
107 https://doi.org/10.1002/art.22527 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038726357
108 rdf:type schema:CreativeWork
109 https://doi.org/10.1002/art.23964 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027969659
110 rdf:type schema:CreativeWork
111 https://doi.org/10.1016/j.reuma.2009.10.006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019555626
112 rdf:type schema:CreativeWork
113 https://doi.org/10.1016/j.reuma.2010.03.007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038036734
114 rdf:type schema:CreativeWork
115 https://doi.org/10.1093/rheumatology/kem115 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033991351
116 rdf:type schema:CreativeWork
117 https://doi.org/10.1093/rheumatology/kes082 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053312193
118 rdf:type schema:CreativeWork
119 https://doi.org/10.1111/j.1524-4733.2007.00187.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1045102741
120 rdf:type schema:CreativeWork
121 https://doi.org/10.1136/ard.2008.099291 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046023242
122 rdf:type schema:CreativeWork
123 https://doi.org/10.1136/ard.2008.101659 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003597473
124 rdf:type schema:CreativeWork
125 https://doi.org/10.3310/hta10420 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071138943
126 rdf:type schema:CreativeWork
127 https://www.grid.ac/institutes/grid.411251.2 schema:alternateName Hospital Universitario de La Princesa
128 schema:name Servicio Farmacia, Hospital La Princesa, Madrid, España
129 rdf:type schema:Organization
130 https://www.grid.ac/institutes/grid.497645.d schema:alternateName UCB Pharma (Spain)
131 schema:name Departamento Médico, UCB Pharma, Madrid, España
132 Departamento de Farmacoeconomía, UCB Pharma, Madrid, España
133 rdf:type schema:Organization
134 https://www.grid.ac/institutes/grid.8048.4 schema:alternateName University of Castile-La Mancha
135 schema:name Facultad de Ciencias Jurídicas y Sociales, Universidad de Castilla la Mancha, Cobertizo San Pedro Mártir, S/N, 45071, Toledo, España
136 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...